Leerink Partnrs Issues Negative Outlook for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for shares of Elanco Animal Health in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $0.20 for the quarter, down from their previous forecast of $0.26. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s FY2027 earnings at $1.07 EPS and FY2028 earnings at $1.24 EPS.

Other analysts have also recently issued reports about the company. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler cut their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. UBS Group reduced their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday. Finally, Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $15.00.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $12.02 on Friday. The company’s fifty day simple moving average is $9.89 and its two-hundred day simple moving average is $11.42. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $18.80. The firm has a market cap of $5.97 billion, a PE ratio of 30.05, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the firm posted $0.34 earnings per share. The business’s quarterly revenue was down 1.0% compared to the same quarter last year.

Institutional Trading of Elanco Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in ELAN. FMR LLC boosted its holdings in Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company’s stock worth $487,213,000 after acquiring an additional 37,022,891 shares in the last quarter. Norges Bank bought a new position in Elanco Animal Health in the 4th quarter worth about $47,424,000. Brandes Investment Partners LP grew its position in Elanco Animal Health by 66.9% during the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock valued at $69,405,000 after purchasing an additional 2,296,691 shares during the last quarter. ASR Vermogensbeheer N.V. bought a new stake in Elanco Animal Health during the 1st quarter valued at about $23,744,000. Finally, Freestone Grove Partners LP bought a new stake in Elanco Animal Health during the 4th quarter valued at about $20,396,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.